KLK3 and prostate carcinoma: Blood-specific prostate antigen (PSA) remains the most widely used biomarker in the detection of early prostate cancer, but new biomarkers, like exosomal miRNAs, have been proposed to increase specificity and distinguish aggressive from non-aggressive PCas [9].